Most people are aware of type 1 and type 2 diabetes, but did you know there is a type 3 diabetes as well! It is a more obscure term. Although it is not an accepted medical diagnosis, type 3 diabetes has been discussed in the literature as a possible relationship between insulin resistance in the brain and Alzheimer's disease. This link has been described to help explain how metabolic disorders impact brain health, causing cognitive decline and dementia.

What is Type 3 Diabetes?

Type 3 diabetes is more of a misnomer because it should not be confused with type 3c diabetes, which relates to pancreatic dysfunction. The term "type 3 diabetes," on the other hand, has been loosely used by some scientists to analogously propose that Alzheimer's disease is strongly implicated with insulin resistance in the brain.

This concept was conceptualized by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University in the year 2008. This hypothesis postulated that Alzheimer's disease may be called type 3 diabetes for it bears many similarities with glucose metabolism disorder type 2 diabetes. Their concept arises from the basic principle that insulin is fundamental to blood sugar regulation, but it is also the case with the brain. When brain cells become insulin-resistant, they lose access to glucose, impairing their function.

Research published in the Journal of Diabetes Science and Technology supports this hypothesis by indicating that insulin resistance can be a significant contributor to the occurrence of dementia, also referred to as Alzheimer's. The symptoms of memory loss and diminished reasoning are associated with impaired glucose metabolism in the body, especially in the cerebral tissue.

Symptoms of Type 3 Diabetes

Although type 3 diabetes is not a "medical term," its symptoms correlate well with Alzheimer's diseases that are known to reduce the ability to think in an efficient manner and bring down brain health. These signs are:

- Loss of memory, especially short-term.

- Poor judgment and judgment ability

- Failure in recognizing people or places familiar once.

- Failure in the process of reading, writing or processing numbers

- Anxiety, agitation, or mood changes.

- Disorganized thoughts or confusion

- Lack of impulse control

As the disease advances, patients may be afflicted with severe complications including an inability to swallow or control their bodily functions. In the final stages, most patients die from fatal complications such as aspiration pneumonia.

Causes of Type 3 Diabetes

This may not be well understood with regards to type 3 diabetes, or the exact link between insulin resistance and Alzheimer's disease. Some identified contributing factors include the following:

1. Insulin Resistance

Insulin acts as an important regulatory mechanism of brain functions such as memory and cognition. The reduction in insulin signaling may impair metabolism of brain cells, thus bringing about neurodegeneration.

2. Type 2 Diabetes

These diseases show a strong relationship and those individuals diagnosed with type 2 diabetes have double chances of getting Alzheimer's. In the two, the main causes can be chronic inflammation, oxidative stress, and a defect in glucose metabolism.

3. Environmental and Lifestyle Factors

Insulin resistance associated with obesity, stress, and an unhealthy diet is considered a cause that may increase the chances of Alzheimer's disease.

Researches in Frontiers in Neuroscience and The Lancet Neurology have also highlighted that drugs used for antidiabetic medication may be crucial for the prevention or at least slowing down the course of Alzheimer's.

Treatments for Type 3 Diabetes

In 2022, in a study in Pharmaceuticals, researchers studied biomarker uptake in brain regions implicated in the faulty uptake and metabolism of blood sugar in Alzheimer’s patients.

Emerging Therapies

Research into such treatments as intranasal insulin has also been promising. Intranasal delivery of insulin directly to the brain has been reported to enhance glucose uptake by brain cells, improve memory, and boost cognitive performance. While such clinical trials have been shown to be successful, additional research is needed for safety and efficacy.

Medications

For patients being aggressive or agitated, antipsychotic drugs may be prescribed; however, therapies such as cognitive rehabilitation as well as cognitive stimulation therapy serve to preserve memory and executive function.

Lifestyle Interventions

Diet, exercise, and stress management are critical in preventing and managing insulin resistance. A review in the Journal of Alzheimer's Disease also highlighted the benefits of Kirtan Kriya meditation, which can regulate genes involved in insulin and glucose metabolism, improve sleep, and reduce inflammation.

Can Type 3 Diabetes Be Prevented?

Although type 3 diabetes is not officially recognized, its connection to Alzheimer’s disease underscores the importance of proactive measures for brain health. Some prevention strategies include:

1. Healthy Diet

Consuming a balanced diet rich in antioxidants, whole grains, and healthy fats may support brain health.

2. Regular Exercise

Physical activity improves insulin sensitivity, reduces inflammation, and enhances overall metabolic health.

3. Stress Reduction

Mindfulness practices, including meditation, have been shown to lower stress levels, which can reduce the risk of cognitive decline.

The term type 3 diabetes brings out the complex relationship between metabolic disorders and brain health. Even though it is not a recognized medical condition, the concept emphasizes the crucial role of insulin in brain function and its possible contribution to Alzheimer's disease. Continued research will hopefully provide hope for therapies such as intranasal insulin and lifestyle modifications.

Epilepsy is one of the most common neurological disorders and a leading cause of disability worldwide. Research has suggested that associated conditions, such as stigma, anxiety, and depression, can sometimes be more debilitating than the seizures themselves.

Stigma related to epilepsy can exist at both societal and individual levels, with many patients experiencing feelings of shame, fear, discrimination, and social isolation.

Now, research led by AIIMS New Delhi has suggested that yoga may help reduce epilepsy-related stigma while also improving seizure control. The 2023 study, published in Neurology, found that yoga-based interventions may offer benefits for both mental well-being and disease management.

“Yoga has been clinically proven to reduce the ‘felt stigma’ associated with epilepsy. By alleviating anxiety and improving both mindfulness and overall quality of life, mind-body interventions empower individuals to feel more in control and less socially isolated,” lead author Dr. Manjari Tripathi, Head of the Department of Neurology at AIIMS, told HealthandMe.

What Did the Study Find?

According to Dr. Manjari, the study identified three key benefits of yoga for people living with epilepsy:

• Stigma Reduction: Patients who participated in a six-month yoga and psychoeducation program reported a significant reduction in perceived stigma compared with the control group.

• Improved Seizure Control: The yoga intervention was associated with a higher rate of seizure reduction. "Participants were more than four times as likely to experience a greater than 50% reduction in seizures and were significantly more likely to achieve complete seizure remission," Dr. Manjari told HealthandMe.

• Better Mental Health: Yoga practice was linked to lower anxiety levels, improved emotional regulation, and reduced cognitive impairment.

Also read: Yoga's Increasing Role As Great Soft Power And Preventive Healthcare: Ayush Secretary

Dr. Rajesh Sagar, Professor of Psychiatry at AIIMS, told HealthandMe that yoga reduced the burden of epilepsy and improved the overall quality of life in epilepsy patients by reducing the perceived stigma. The overall quality of life was also improved in the yoga group.

How Was the Study Conducted?

Read More: Congo Ebola Cases Rise to 676; FIFA World Cup Team Arrives in US After Quarantine

Researchers conducted a randomized clinical trial involving 160 adults with epilepsy who were followed for six months. Participants were assigned either a structured yoga program or a sham yoga intervention, while both groups also received epilepsy-related psychoeducation.

The yoga program included loosening exercises , breathing techniques, meditation, and positive affirmations.

While the impact on seizure frequency was reduced compared with the control group, the researchers cautioned that larger studies are needed to conclusively determine the effect of yoga on seizure control.

Yoga For Mental Health

Further, mood disturbances have been common among people with epilepsy and often remain inadequately addressed, particularly in developing countries.

According to the researchers, yoga may offer a scalable and accessible option for helping patients manage these challenges alongside conventional treatment.

Dr. Rajesh further told HealthandMe that yoga has well-established benefits for mental health.

“Yoga is important in mental health care, and it has been found that the three important things, which are pranayama, that is, breathing techniques, asanas, that is, physical posture, and dhyana, that is, meditation, have a positive effect on anxiety and even depression, and also improve sleep".

He added that yoga can help reduce stress, improve mood, lower anxiety levels, and enhance sleep quality.

“There is substantial evidence from around the world showing that yoga can benefit people living with certain mental health disorders,” he said.

Every morning, millions begin their day with a quick breakfast and blood pressure (BP) medication swallowed mechanically. But what happens when BP remains uncontrolled despite medicines? Uncontrolled hypertension is one of the most underestimated health threats. Often called the silent killer, it quietly damages the heart, brain, kidneys, and blood vessels.

The BP reading on the cuff captures only a visible measurement. BP that remains above goal over time despite treatment is concerning. Hypertension affects approximately 1.4 billion adults worldwide. Studies suggest that almost 54% of Indian patients have uncontrolled hypertension even while taking ≥2 medications. Thus, treatment does not necessarily mean control.

Why Does BP Control Matter?

Global organizations recommend stricter BP targets, aiming for readings below 130/80 mmHg or even 120 mmHg if tolerated. Studies show that each 10 mmHg reduction in systolic BP can decrease the risk of major cardiovascular events by 20%, stroke by 27%, heart failure by 28%, and death by 13%.

On the other hand, uncontrolled hypertension increases the risk of heart attacks, strokes, heart failure, end-stage kidney disease, type 2 diabetes, and death.

But What If The Numbers Don’t Change Despite Medication?

In persistently uncontrolled hypertension that other causes cannot explain, a hidden culprit called aldosterone is an under-recognized driver. Normally, aldosterone balances sodium and water to regulate BP.

However, in patients with uncontrolled hypertension, aldosterone production may remain abnormally high, causing sodium and fluid buildup, increasing BP.

Approximately 30% of patients with hypertension may have aldosterone dysregulation, and patients with resistant hypertension, obesity, type 2 diabetes, sleep apnea, and hypokalemia are at greater risk. Nearly 10–20% of patients with hypertension are treatment resistant, increasing their risk. In these patients, aldosterone dysregulation could be an important cause.

It is time to look beyond the cuff, as uncontrolled hypertension is a chronic, progressive, and often silent condition with serious consequences. Improving patient outcomes requires greater urgency, earlier intervention, better treatment optimization, and stronger awareness of underlying drivers such as aldosterone.

It is time to identify and treat the root causes of uncontrolled hypertension, so that patients can regain lasting BP control.

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.

Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.

Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).

The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.

"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.

What Did the Study Find?

Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?

The researchers analyzed more than 4,900 patients with IBD and discovered that:

• A substantial subset of patients shows autoimmune responses to one of the guardians of the immune system, interleukin-10 (IL-10), which leads to uncontrolled inflammation.
• This damaging immune response is the mechanism for one of the strongest known genetic risk factors for IBD.

Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.

The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.

The Genetic Link

Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s

The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.

The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.

The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.

What Could This Mean for Patients?

The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.

What Is IBD?

As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.

Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.

What Are The Symptoms Of IBD That People Usually Ignore?

• Diarrhea or changes in bowel movements
• Stomach pain
• Fatigue
• Nausea
• Weight loss

• Dehydration
• Increased risk of colon and rectal cancers
• Low red blood cell count (anemia)
• Reduced bone density
• Joint pain
• Skin changes
• Eye irritation
• Delayed or impaired growth in some children.